These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 112475)

  • 1. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin.
    Harter HR; Burch JW; Majerus PW; Stanford N; Delmez JA; Anderson CB; Weerts CA
    N Engl J Med; 1979 Sep; 301(11):577-9. PubMed ID: 112475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.
    Pedersen AK; FitzGerald GA
    N Engl J Med; 1984 Nov; 311(19):1206-11. PubMed ID: 6436696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
    J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shunt thrombosis prevention in hemodialysis patients--a double-blind, randomized study: pentoxifylline vs placebo.
    Radmilović A; Borić Z; Naumović T; Stamenković M; Muśikić P
    Angiology; 1987 Jul; 38(7):499-506. PubMed ID: 3304027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations.
    Chesebro JH; Fuster V; Elveback LR; Clements IP; Smith HC; Holmes DR; Bardsley WT; Pluth JR; Wallace RB; Puga FJ
    N Engl J Med; 1984 Jan; 310(4):209-14. PubMed ID: 6361561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
    Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
    J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of platelet prostaglandin synthetase by oral aspirin.
    Burch JW; Stanford N; Majerus PW
    J Clin Invest; 1978 Feb; 61(2):314-9. PubMed ID: 413839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency.
    Chesebro JH; Clements IP; Fuster V; Elveback LR; Smith HC; Bardsley WT; Frye RL; Holmes DR; Vlietstra RE; Pluth JR; Wallace RB; Puga FJ; Orszulak TA; Piehler JM; Schaff HV; Danielson GK
    N Engl J Med; 1982 Jul; 307(2):73-8. PubMed ID: 7045659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.
    Feldman M; Cryer B; Mallat D; Go MF
    Am J Gastroenterol; 2001 Jun; 96(6):1751-7. PubMed ID: 11419825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
    Turpie AG
    Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining patency of tunneled hemodialysis catheters--efficacy of aspirin compared to warfarin.
    Obialo CI; Conner AC; Lebon LF
    Scand J Urol Nephrol; 2003; 37(2):172-6. PubMed ID: 12745728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study.
    Bachert C; Chuchalin AG; Eisebitt R; Netayzhenko VZ; Voelker M
    Clin Ther; 2005 Jul; 27(7):993-1003. PubMed ID: 16154478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
    Finazzi G;
    Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Double-blind study for the prevention of postoperative thrombosis].
    Encke A; Stock C; Dumke HO
    Chirurg; 1976 Dec; 47(12):670-3. PubMed ID: 1001131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.
    Weksler BB; Pett SB; Alonso D; Richter RC; Stelzer P; Subramanian V; Tack-Goldman K; Gay WA
    N Engl J Med; 1983 Apr; 308(14):800-5. PubMed ID: 6339916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of renal function with selective thromboxane antagonism in lupus nephritis.
    Pierucci A; Simonetti BM; Pecci G; Mavrikakis G; Feriozzi S; Cinotti GA; Patrignani P; Ciabattoni G; Patrono C
    N Engl J Med; 1989 Feb; 320(7):421-5. PubMed ID: 2643773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.